October 21, 2021
Aduhelm Administration Remains a Trickle, ARIA a Concern
By: Madolyn Bowman Rogers
While three other Alzheimer’s immunotherapies are barreling down the approval pike, the first one to have nabbed a marketing license continues to tread an uncertain path. Several hospital systems have chosen not to provide the drug, and some insurers refuse to cover its cost. Thus far, only a smattering of patients are getting aducanumab infusions.
Among physicians, adoption is being held back by both skepticism and skimpy insurance coverage. In a recent survey of 74 neurologists by the market research firm Spherix Global Insight, 84 percent said they had lost confidence in the FDA over the last year, partly due to the agency’s aducanumab decision… (read more)